Maintenance Rituximab or Observation after Frontline Treatment with Bendamustine-Rituximab for Follicular Lymphoma

Bendamustine (B) with rituximab (R) is a standard frontline treatment for medically fit follicular lymphoma (FL) patients. The safety and efficacy of maintenance rituximab (MR) after BR induction has not been formally compared to observation for FL, resulting in disparate practice patterns. Prospect...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Br J Haematol
Главные авторы: Hill, Brian T., Nastoupil, Loretta, Winter, Allison M., Becnel, Melody R., Cerhan, James R., Habermann, Thomas M., Link, Brian K., Maurer, Matthew J., Fakhri, Bita, Reddy, Prathima, Smith, Stephen D., Mukhija, Dhruvika, Jagadeesh, Deepa, Desai, Amrita, Alderuccio, Juan Pablo, Lossos, Izidore S., Mehra, Pooja, Portell, Craig A., Goldman, Max L., Calzada, Oscar, Cohen, Jonathon B., Hussain, Mohammad Junaid, Ghosh, Nilanjan, Caimi, Paolo, Tiutan, Timothy, Martin, Peter, Kodali, Abhigna, Evens, Andrew M., Kahl, Brad S.
Формат: Artigo
Язык:Inglês
Опубликовано: 2018
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6486816/
https://ncbi.nlm.nih.gov/pubmed/30575016
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.15720
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы